# The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.

**Tumor:** Cáncer gástrico/UGE
**Autores:** Rencuzogullari A, Karahan SN, Selcukbiricik F et al
**Revista:** J Surg Oncol (2024)
**PMID:** 39400342 | **PMCID:** PMC12044282
**DOI:** [10.1002/jso.27934](https://doi.org/10.1002/jso.27934)
**Fuente:** PubMed Central (open access)

## Relevancia
Cáncer gástrico/UGE tratado con quimioterapia perioperatoria (FLOT/MAGIC) o inmunoterapia: documenta downstaging ganglionar, valor pronóstico de ypN0 y rendimiento ganglionar tras NAC. Comparable al paradigma mamario: ypN0 tras quimioterapia neoadyuvante es marcador pronóstico fuerte y guía la linfadenectomía D2.

## Abstract
The FLOT 4-AIO trial established the docetaxel-based regimen's superiority over epirubicin-based triplet therapy in terms of survival rates and acceptable toxicity for locally advanced resectable gastric (LARGC). Yet, fewer than half of the patients achieved completion of eight prescribed FLOT cycles. We proposed that administering all FLOT cycles in the form of total neoadjuvant therapy may improve completion rates and downstaging. This study contrasted total neoadjuvant therapy (FLOT x8) with standard neoadjuvant therapy (FLOT 4+4) for patients LARGC adenocarcinoma who underwent curative resection with routine D2 lymphadenectomy, focusing on histopathological outcomes, toxicity, and survival outcomes.

We reviewed patients with histologically confirmed advanced clinical stage cT2 or higher, nodal positive stage (cN+), or both, with resectable gastric tumors and no distant metastases (January 2017 to July 2023). We divided patients into two groups, FLOT 4+4 and FLOT x8; FLOT 4+4 patients underwent four preoperative and four postoperative bi-weekly cycles of docetaxel, oxaliplatin, leucovorin, and fluorouracil, while FLOT x8 patients received all eight cycles preoperatively after a gradual practice change starting from January 2020. Propensity score matching adjusted for age, clinical stage, tumor location, and histology.

Of the 77 patients in the FLOT x8 group, 37 were propensity-matched to an equal number in the FLOT 4+4 group. Demographics, duration of surgery, and hospital stay showed no significant differences between the groups. The FLOT x8 group exhibited a significantly higher all-cycle completion rate at 89.1% compared to FLOT 4+4's 67.6% (p&#x2009;<&#x2009;0.01). Both groups demonstrated comparable hematological and non-hematological toxicity rates, Clavien-Dindo &#x2265;&#x2009;3 complications, and CAP tumor regression grades. The mean number of harvested lymph nodes was 42.5 and 41.2 in the FLOT 4+4 and FLOT x8 groups, respectively. Similar rates of disease-free survival and overall survival were noted in both groups, despite a trend toward a higher pathological complete response rate, albeit not statistically significant (8.1% vs. 18.9%, p&#x2009;=&#x2009;0.29), in the FLOT x8 group at a median follow-up of 36 months.

Total neoadjuvant therapy with the FLOT x8 protocol corresponds to higher treatment completion rates, a safety profile similar to standard perioperative therapy, and a twofold increase in complete pathological response. Further research on long-term oncological outcomes is needed to confirm the effectiveness of total neoadjuvant therapy.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12044282/

---
*Datos de PubMed. Citar: doi 10.1002/jso.27934*
